Stockreport

Nuvation Bio (NUVB) Is Up 8.6% After Expanding Safusidenib Into Phase 3 Registrational Trial - Has The Bull Case Changed? [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF broadening eligibility to include higher-grade IDH1-mutant astrocytoma after standard-of-care treatment. This shift moves safusidenib closer to a potential second comm [Read more]